leuprolide
leuprolide: 23 clinical trials tracked.
leuprolide evidence translation
What we can confirm
23 tracked trials
What it means
What to watch
Prepared research question
What is verified about leuprolide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (23)showing 10 most recent
Neoadjuvant ADT and Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in NCCN High-risk and Molecularly Stratified Prostate Cancer Patients
Primary endpoint: Proportion of patients who achieve Minimal residual disease (MRD)
Phase II Randomized Trial of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC).
Primary endpoint: Composite progression free survival
Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)
Primary endpoint: Proportion of participants with ultrasensitive estradiol concentration > 10 pg/ml
A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer
Primary endpoint: Proportion of patients with minimal residual disease
Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: The REVELUTION-2 Trial
Primary endpoint: Incidence of ambulatory systolic blood pressure (BP) > 140 or diastolic > 90 (measurement on 2 separate days)
A Comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on Cardiovascular Function and Biomarkers During Standard of Care Combined ADT (Androgen Deprivation Therapy)-Radiation for Prostate Cancer
Primary endpoint: Physiologic alterations in cardiopulmonary function - Myocardial perfusion
MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Primary endpoint: Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years
RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer
Primary endpoint: 9-month Quality of Life (QOL) Score
An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients With Central (Gonadotropin-Dependent) Precocious Puberty (Casppian Study)
Primary endpoint: Efficacy of Leuprolide Mesylate (FP-001 42 mg)